Hoppe S - Search Results

1

High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.

Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F; French Cowden Disease Network. Bubien V, et al. Among authors: hoppe s. J Med Genet. 2013 Apr;50(4):255-63. doi: 10.1136/jmedgenet-2012-101339. Epub 2013 Jan 18. J Med Genet. 2013. PMID: 23335809 Free article.

2

[Prophylactic mastectomy and occult cancer: a ten-year experience at a cancer center].

Mangiardi-Veltin M, Chamming's F, Jaffre A, Rousvoal A, Tunon de Lara C, Brouste V, Hoppe S, Sénéchal C. Mangiardi-Veltin M, et al. Among authors: hoppe s. Bull Cancer. 2021 Nov;108(11):999-1009. doi: 10.1016/j.bulcan.2021.05.007. Epub 2021 Sep 21. Bull Cancer. 2021. PMID: 34556291 French.

3

[Oncofertility and breast cancer: Where have we come from, where are we going?].

Chirol A, Debled M, Fournier M, Papaxanthos A, Hoppe S, Brouste V, Conri V, Bonnefoi H, Von Théobald P, Mathoulin S, Hocké C, Tunon de Lara C. Chirol A, et al. Among authors: hoppe s. Bull Cancer. 2015 Jun;102(6):489-96. doi: 10.1016/j.bulcan.2015.04.004. Epub 2015 May 16. Bull Cancer. 2015. PMID: 25991386 Free article. French.

4

Diagnostic accuracy of breast MRI for patients with suspicious nipple discharge and negative mammography and ultrasound: a prospective study.

Boisserie-Lacroix M, Doutriaux-Dumoulin I, Chopier J, Boyer B, Depetiteville MP, Hoppe S, Brouste V, Chamming's F. Boisserie-Lacroix M, et al. Among authors: hoppe s. Eur Radiol. 2021 Oct;31(10):7783-7791. doi: 10.1007/s00330-021-07790-4. Epub 2021 Apr 13. Eur Radiol. 2021. PMID: 33846843

5

SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.

Laurent E, Begueret H, Bonhomme B, Veillon R, Thumerel M, Velasco V, Brouste V, Hoppe S, Fournier M, Grellety T, MacGrogan G. Laurent E, et al. Among authors: hoppe s. Am J Surg Pathol. 2019 Mar;43(3):293-302. doi: 10.1097/PAS.0000000000001216. Am J Surg Pathol. 2019. PMID: 30628926

6

Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.

Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G. Pinard C, et al. Among authors: hoppe s. Breast Cancer Res Treat. 2020 Jan;179(1):11-23. doi: 10.1007/s10549-019-05437-z. Epub 2019 Sep 16. Breast Cancer Res Treat. 2020. PMID: 31529299

7

Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases.

Bobin M, Zacharatou C, Sargos P, Brouste V, Lisbona A, Mahé MA, Noël G, Halley A, Feuvret L, Gras L, Hoppe S, de Figueiredo BH, Kantor G. Bobin M, et al. Among authors: hoppe s. Radiat Oncol. 2017 Jan 31;12(1):32. doi: 10.1186/s13014-017-0768-1. Radiat Oncol. 2017. PMID: 28143487 Free PMC article.

8

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study.

Mathoulin-Pélissier S, Chevreau C, Bellera C, Bauvin E, Savès M, Grosclaude P, Albert S, Goddard J, Le Guellec S, Delannes M, Bui BN, Mendiboure J, Stoeckle E, Coindre JM, Kantor G, Kind M, Cowppli-Bony A, Hoppe S, Italiano A. Mathoulin-Pélissier S, et al. Among authors: hoppe s. Ann Oncol. 2014 Jan;25(1):225-31. doi: 10.1093/annonc/mdt407. Epub 2013 Nov 26. Ann Oncol. 2014. PMID: 24285018 Free PMC article.

9

Functional decline in older patients with cancer receiving first-line chemotherapy.

Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L, Vogt L, Dauba J, Houédé N, Bellera CA, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, Soubeyran P. Hoppe S, et al. J Clin Oncol. 2013 Nov 1;31(31):3877-82. doi: 10.1200/JCO.2012.47.7430. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062399

10

PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).

Grellety T, Cousin S, Letinier L, Bosco-Lévy P, Hoppe S, Joly D, Penel N, Mathoulin-Pelissier S, Italiano A. Grellety T, et al. Among authors: hoppe s. BMC Cancer. 2016 Oct 4;16(1):768. doi: 10.1186/s12885-016-2819-7. BMC Cancer. 2016. PMID: 27716199 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters